臨床外科72巻10号

2017年10月発行

特集 Conversion Surgery—進行消化器がんのトータル治療戦略

総論

腫瘍内科医からみたConversion Surgery

著者： 宮本敬大¹ 加藤健¹

所属機関： ¹国立がん研究センター中央病院消化管内科

ページ範囲：P.1171 - P.1175

文献概要

【ポイント】
◆conversion surgeryは，根治不能な病態に根治可能性を見出す大変魅力的な治療方法である．しかし，症例が「根治不能に近い病態」であることを念頭において，慎重に判断し説明をする必要がある．
◆conversion surgeryへと導いてくれるinduction therapyを行ううえで，治療強度を落とさないために，有害事象のマネージメントは重要であり，同時に，周術期合併症を増加させないために，治療の終了時期や休薬のタイミングを適切に判断する必要がある．
◆患者の治療方針を決定する際には，内科，外科，病理医，放射線診断医など，領域横断的なディスカッションを行う必要がある．

参考文献

1）Ando N, Kato H, Igaki H, et al：A randomized trial of post- operative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage Ⅱ/Ⅲ squamous cell carcinoma of the thoracic esophagus（JCOG9907）. Ann Surg Oncol 19：68-74, 2012

2）Yokota T, Kato K, Hamamoto Y, et al：Phase Ⅱ study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer 22：1328-1334, 2016

3）Tsuburaya A, Mizusawa J, Tanaka Y, et al：Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg 101：653-660, 2014

4）Yamada Y, Higuchi K, Nishikawa K, et al：Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol 26：141-148, 2015

5）Bang YJ, Van Cutsem E, Feyereislova A, et al：Trastuzumab in combination with chemotherapy versus chemo- therapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer（ToGA）：a phase Ⅲ, open-label, randomized controlled trial. Lancet 376：687-697, 2010

6）Suzuki T, Tanabe K, Taomoto J, et al：Preliminary trial of adjuvant surgery for advanced gastric cancer. Oncol Lett 1：743-747, 2010

7）Iida T, Nomori H, Shiba M, et al：Prognostic factors after pulmonary metastasectomy for colorectal cancer and rationale for determining surgical indications：a retrospective analysis. Ann Surg 257：1059-1064, 2013

8）Adam R, Delvart V, Pascal G, et al：Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy：a model to predict long-term survival. Ann Surg 240：644-657, 2004

9）Adam R, Wicherts DA, de Haas RJ, et al：Patients with initially unresectable colorectal liver metastases：is there a possibility of cure? J Clin Oncol 27：1829-1835, 2009

10）大腸癌研究会（編）：大腸癌治療ガイドライン医師用2016年版．金原出版，2016

11）NCCN Guidelines［http://www.nccn.org/professionals/physician_gls/f_guidelines.asp］

12）Van Cutsem E, Cervantes A, Adam R, et al：ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27：1386-1422, 2016

13）Primrose J, Falk S, Finch-Jones M, et al：Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis：The New EPOC randomised controlled trial. Lancet Oncol 15：601-611, 2014

14）Gruenberger T, Bridgewater J, Chau I, et al：Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer：the OLIVIA multinational randomised phase Ⅱ trial. Ann Oncol 26：702-708, 2015

15）Cauchy F, Aussilhou B, Dokmak S, et al：Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Ann Surg 256：746-752, 2012

16）Gruenberger B, Tamandl D, Schueller J, et al：Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 26：1830-1835, 2008

17）Reddy SK, Morse MA, Hurwitz HI, et al：Addition of bevacizumab to irinotecan-and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206：96-106, 2008

18）Ychou M, Rivoire M, Thezenas S, et al：A randomized phase Ⅱ trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol 20：4289-4297, 2013

19）Folprecht G, Gruenberger T, Bechstein W, et al：Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept（CELIM study）. Ann Oncol 25：1018-1025, 2014